These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 28718092)

  • 1. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Med Oncol; 2017 Aug; 34(8):141. PubMed ID: 28718092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G; Basappa NS; North S; Ghosh S; Kolinsky M
    Curr Oncol; 2024 Aug; 31(9):5080-5087. PubMed ID: 39330003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
    Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
    Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
    Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study.
    Takai M; Kato S; Nakano M; Fujimoto S; Iinuma K; Ishida T; Taniguchi M; Tamaki M; Uno M; Takahashi Y; Komeda H; Koie T
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):238-244. PubMed ID: 32970933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
    Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):576-583. PubMed ID: 29275450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
    Kosaka T; Shinojima T; Morita S; Oya M
    Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
    Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
    BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.